40M.F NANEXA AB
- Market cap
- EUR 168M
- P/E
- 12.5x
- P/B
- 5.92x
- ROE
- 56.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 40M.F undervalued?
Graham number40M.F trades 81.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NANEXA AB fundamental analysis
No fundamental analysis for NANEXA AB yet.
NANEXA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NANEXA AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug f…
Full company profileNANEXA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NANEXA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.37M | 2.86M | 29.3M | 24.4M | 36.1M | 308M |
| Gross Profit | 18.0M | 27.2M | 59.2M | 46.7M | 55.9M | 326M |
| Operating Income | -35.7M | -58.3M | -76.3M | -26.4M | -8.30M | 173M |
| EBITDA | - | -47.5M | -16.2M | -13.7M | 4.16M | 187M |
| Net Income | -36.0M | -58.6M | -76.4M | -24.9M | -11.4M | 172M |
| EPS | -0.71 | -1.16 | -0.56 | -0.18 | -0.07 | 0.90 |
| Balance Sheet | ||||||
| Total Assets | 165M | 170M | 132M | 91.8M | 138M | 327M |
| Total Liabilities | 13.7M | 61.1M | 36.4M | 20.9M | 36.6M | 21.0M |
| Shareholders' Equity | 151M | 109M | 95.8M | 70.9M | 102M | 306M |
| Cash & Short-term Investments | 106M | 81.2M | 15.2M | 10.3M | 44.6M | 44.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -25.1M | -7.87M | -42.7M | -26.4M | -1.46M | -42.4M |
| Capital Expenditure | 25.8M | 35.4M | 34.2M | 28.1M | 24.7M | 30.5M |
| Free Cash Flow | -50.9M | -43.3M | -76.9M | -54.6M | -26.2M | -72.8M |
| Ratios | ||||||
| ROE | -23.8% | -53.7% | -79.7% | -35.1% | -11.2% | 56.4% |
| ROA | -21.8% | -34.4% | -57.8% | -27.1% | -8.2% | 52.8% |
| Net Profit Margin | -1,516.4% | -2,047.9% | -260.5% | -102.2% | -31.5% | 56.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NANEXA AB dividends
NANEXA AB has not paid dividends in the last 5 fiscal years.
Who owns NANEXA AB
- Insiders 27.24%
- Institutions 7.27%
- Public & others 65.50%
- Shares outstanding 191M
- Free float 149M
NANEXA AB company profile
- Company name
- NANEXA AB
- Ticker
- 40M.F
- ISIN
- SE0007074166
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 17
- Fiscal year end
- December
- Address
- Virdings Allé 2, Uppsala, Sweden, 75450
- Phone
- 46 18 10 03 00
- Website
- nanexa.com
About NANEXA AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
NANEXA AB management
9- Mr. David WestbergChief Executive Officer · born 1960
- Mr. Marten RoothCo-Founder & CTO · born 1977
- Mr. Anders JohanssonCo-Founder & Head of Intellectual Property · born 1976
- Ms. Cecilia Danckwardt-LilliestromChief Financial Officer · born 1961
- Mr. Mikael AspHead of QA & Special Advisor · born 1962
- Mr. Joel HellrupHead of Pharmaceutical R&D · born 1983
- Polla RoufHead of ALD R&D
- Ms. Bridget Lacey B.Sc.Chief Business Officer
- Mr. Otto Skolling M.ScDirector of Business Development · born 1961